I can't heled with the later, but the r117h is considered a residual function mutation and kalydeco helps it. FDA panel just recommended approving label for those with r117h. Study only supports dr over 18 but obviously helps younger too, but since you're over 18 not an issue. Eu is looking to expand label for r117h for kalydeco only over 18. I don't know what Canada is considering. Given delay in aapproach for kalydeco reimbursement I fear Canada might be a couple years behind...but the good news is that there is a pill that will hel given your mutation. Also, if it were me, I'd talk to doctor about wanting to do the 661 and kalydeco combined study that will enroll in 2015 first half of year for those with residual function mutations since the combo will help more and get you access to drugs much sooner. If you can get your other medical issues stable in meantime that would be best so they don't exclude you. For now though there is lots to do to get you to best feeling you'll likely have had in years. And yes r117h is co sidered mild but hits more heavily in adulthood, as seen by study results. Let me know if this doesn't make sense.